| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_616f7b1d1b9e3c904aba8ff2513922e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_efb531ce8bc9645512926cbf2b48ae2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C40B30-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B30-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 |
| filingDate |
2011-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93cfe8a304142d46199f702807ebc694 |
| publicationDate |
2017-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9801886-B2 |
| titleOfInvention |
Thrombocyte inhibition via vivo-morpholino knockdown of alpha IIb |
| abstract |
Novel compounds comprising a guanidine-rich head covalently coupled to one or more oligonucleotide antisense sequences which are useful to modulate blood coagulation by affecting the expression of integrin αIIb or β3 are described herein. This invention also includes pharmaceutical compositions containing these compounds, with or without other therapeutic agents, and to methods of using these compounds as inhibitor of platelet aggregation, as thrombolytics, and/or for the treatment of other thromboembolic disorders. Vivo-MOs, which include eight guanidine groups dendrimerically arranged in the guanidine-rich head and two synthetic antisense morpholino oligonucleotides, are representative compounds of the present invention. |
| priorityDate |
2010-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |